Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1.

Timaner M, Kotsofruk R, Raviv Z, Magidey K, Shechter D, Kan T, Nevelsky A, Daniel S, de Vries EGE, Zhang T, Kaidar-Person O, Kerbel RS, Shaked Y.

Oncogene. 2020 Jan;39(1):187-203. doi: 10.1038/s41388-019-0971-7. Epub 2019 Aug 29.

2.

Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.

Beyar-Katz O, Magidey K, Reiner-Benaim A, Barak N, Avivi I, Cohen Y, Timaner M, Avraham S, Hayun M, Lavi N, Bersudsky M, Voronov E, Apte RN, Shaked Y.

Mol Cancer Res. 2019 Nov;17(11):2331-2340. doi: 10.1158/1541-7786.MCR-19-0487. Epub 2019 Aug 13.

PMID:
31409628
3.

Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy.

Shaked Y, Pham E, Hariharan S, Magidey K, Beyar-Katz O, Xu P, Man S, Wu FT, Miller V, Andrews D, Kerbel RS.

Cancer Res. 2016 Oct 15;76(20):5983-5993. Epub 2016 Aug 28.

4.

Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy.

Beyar-Katz O, Magidey K, Ben-Tsedek N, Alishekevitz D, Timaner M, Miller V, Lindzen M, Yarden Y, Avivi I, Shaked Y.

J Pathol. 2016 Jul;239(3):262-73. doi: 10.1002/path.4723. Epub 2016 Apr 29.

PMID:
27037906

Supplemental Content

Loading ...
Support Center